January 1, 2012Thrombosis and Haemostasis
Contemporary use of glycoprotein IIb/IIIa inhibitors
Key result
Glycoprotein IIb/IIIa inhibitors remain potentially beneficial during coronary interventions for high-risk patients with acute myocardial infarction lacking adequate oral antiplatelet pretreatment.
Structured PICO
P
Population
Patients with acute coronary syndromes, particularly those undergoing percutaneous coronary interventions, including acute ST-elevation and non-ST-elevation myocardial infarctions.
I
Intervention
Intravenous glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, and tirofiban)
While their indications have become more restricted with the advent of modern oral P2Y12 inhibitors, intravenous glycoprotein IIb/IIIa inhibitors remain useful in high-risk ACS patients undergoing PCI without adequate oral antiplatelet pretreatment.
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Hypothesis-generating for selective GP IIb/IIIa use in high-risk AMI PCI without pretreatment; prospective trials needed to confirm benefit.
Cite This Study
Würtz et al. (2012) conducted a review in Acute coronary syndromes. Glycoprotein IIb/IIIa inhibitors was evaluated. Glycoprotein IIb/IIIa inhibitors remain potentially beneficial during coronary interventions for high-risk patients with acute myocardial infarction lacking adequate oral antiplatelet pretreatment.